|
||
| |||||||
|
-
North America’s most effective partnering forum - April
3-4, 2003, San Francisco, CA, USA The
information exchange and company selections that lead up to active
participation in this uniquely effective and efficient partnering forum
have now started. Pharma
License Exchange™ still has limited space available for pharma and
biotech companies with a desire to out-license, in-license or establish
other types of partnerships or strategic alliances for their products and
technologies. Innovative
Concept Pharma
License Exchange™ is an innovative concept that was developed by
Montalier International Ltd. to provide an efficient and effective
partnering alternative for business development and licensing executives. Pharma
License Exchange™ consists of 4
main elements: ·
20
meeting slots over 2 days for one-to-one, pre-informed and pre-scheduled
meetings ·
Optimal
scheduling, supported by sophisticated computer software ·
Pre-event
selection of meeting partners ·
Web-based
pre-event information exchange Pharma
License Exchange™ gathers a select group of pharma and biotech
executives with legitimate licensing mandates that are all there to
explore the best licensing opportunities and to establish personal
contacts, without the distractions of lectures and lengthy panel
discussions. Meeting
Expectations “We
feel confident that our innovative concept, focusing solely on one-to-one
personal meetings, meets the expectations of business development and
licensing executives”, said Mr. Vidar Bentzen, Montalier’s CEO. “The
success of Pharma License Exchange™ is measured by the opportunities of
each participant to establish relationships with relevant people. To our
knowledge, it is the only pharma and biotech industry event worldwide that
in fact rejects registrations from anyone not specifically seeking product
or technology licensing.” Participants’
Experiences Following
the latest Pharma License Exchange™ forum, which took place in
Cambridge, MA, in October 2002, Mr. Tim O’Halla, Director of New
Products Marketing at Ferndale
Laboratories, Inc., summed up his experiences as follows: "Pharma
License Exchange™ is uniquely effective for a number of reasons, among
them: 1)
All attendees want and have the authority to make deals. 2)
The "investment" at risk is small, basically your time and the
$1,185 fee. 3)
You get to pick whom you would like to meet with on the basis of their
licensing objectives and company profiles. This way, there is not a lot of
wasted meetings. 4)
The whole process is very efficient. There isn't excess fluff or other
activities that get in the way of getting business done. 5)
I've personally benefited from participation." Sponsors BioSpace
and CanBiotech have signed up as sponsors for the upcoming forum in San
Francisco, April 3-4, 2002. This will undoubtedly contribute to attracting
some of the best licensing opportunities of the year. Limited
Space Up
to a maximum of 80 companies will be admitted in San Francisco and the
places are filling up fast. “We
limit the number of attendees for two main reasons”, said Mr. Bentzen.
“Firstly, our objective is to create a personable atmosphere that
encourages personal networking. Secondly, the challenge of scheduling and
arranging up to 1,520 meetings during the 2 days is a limiting factor in
itself.” Venue The
venue for the San Francisco forum is the distinctive and striking Pan
Pacific Hotel, just a few steps from Union Square in the heart of the
city. Accommodation is offered at an attractive, preferred rate. Purpose
& Focus of the Forum: Pharma
License Exchange™ is designed for a select group of pharma and biotech
companies seeking business opportunities that can shape their future by in-licensing,
out-licensing, co-development, co-marketing, co-promotion, distribution,
acquisition as well as other types of partnerships and strategic
alliances. Its
3 distinct sections offer the participants the opportunity to focus on
Innovations, ie. products and technologies, from pre-clinical projects,
through clinical research Phase I-III, as well as commercialized products
within the Rx and the OTC categories. Who
Should Attend: Pharma
License Exchange™ is designed for decision makers and it serves to
facilitate collaborations between pharma and biotech companies, whether
they are well established or start-ups, that are seeking corporate
partners. The
titles of the participants range from CEOs to managers, with a majority
carrying the title Vice President or Director. Their commonality is
responsibility for business development, licensing, corporate development
or commercial development. Pharma
License Exchange™
is a North American event, but it embraces the pharma and biotech
industries as global enterprises. This is indicated by the geographical
spread of the participants, ie. 63%, 22%, 7%, 7% and 1% for North America,
Europe, Latin America, Asia and the Middle East, respectively Benefits
of Attending: ·
Effective
opportunities for screening attractive business opportunities ·
Optimal
opportunities/time spent ratio ·
Optimal
opportunities/cost ratio ·
Networking with
relevant people with shared focus ·
Development of
personal contacts (reduce “cold calls”) ·
Effective elimination
of offerings that do not fit with your strategic direction Registration
Fee: The
registration fee includes up to 20 one-to-one meetings, pre-event
information exchange and company selection, optimal scheduling, The
Exchange Dinner™, 2 lunches and continuous refreshments in The Exchange
Café™. Registration
fee: US$ 1,185.00. Discounts offered for additional participants and
representatives from academia. Information
and Registration: By
phone: 416 766 3517 By
fax: 416 769 9442 By
e-mail: info@pharlex.com On-line:
www.pharlex.com Conference
Brochure: To
download a PDF version of the Pharma License Exchange™ brochure, please
use the following link: http://www.pharlex.com/next/brochure/PharlexBrochure.pdf For
Further Information, Please Contact: Vidar
Bentzen Montalier
International Ltd. P.O.
Box 84531 2336
Bloor Street West Toronto,
Ontario M6S
1T0 Canada Phone:
416-766-3517 Fax:
416-769-9442 Please
forward this press release to friends & colleagues who might find it
useful. |
|
| ||||||||